Vanguard 7

Страна: Велика Британія

мова: англійська

Джерело: VMD (Veterinary Medicines Directorate)

Активний інгредієнт:

Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae

Доступна з:

Zoetis UK Limited

Код атс:

QI07AI02

ІПН (Міжнародна Ім'я):

Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae

Фармацевтична форма:

Powder and solvent for solution for injection

Тип рецепту:

POM-V - Prescription Only Medicine – Veterinarian

Терапевтична група:

Dogs

Терапевтична области:

Live Viral and Inactivated Bacterial Vaccine

Статус Авторизація:

Authorized

Дата Авторизація:

2005-10-28

Характеристики продукта

Amended pages: December 2023
AN: 02539/2021
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vanguard 7
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Quantity per 1 ml dose:
ACTIVE SUBSTANCES:
Freeze-dried fraction: Vanguard DA
2
Pi
Live attenuated canine distemper virus, strain N-CDV, minimum titre:
10
3.0
CCID
50
*
Live attenuated canine adenovirus Type 2, strain Manhattan, minimum
titre: 10
3.2
CCID
50
*
Live attenuated canine parainfluenzavirus, strain NL-CPI-5, minimum
titre: 10
6.0
CCID
50
*
Liquid fraction: Vanguard CPV-L
Live attenuated canine parvovirus, strain NL-35-D, low passage,
minimum titre: 10
7.0
CCID
50
*
Inactivated _Leptospira canicola_, between 420 and 740 RU**/dose
Inactivated _Leptospira icterohaemorrhagiae_, between 463 to 915
RU**/dose.
* 50% cell culture infectious dose
** Relative units
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for solution for injection
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs to prevent mortality and clinical signs
due to canine
distemper virus infections, to prevent clinical signs including
leucopenia and reduce
viral shedding caused by canine parvovirus (type 2a), to prevent
mortality and clinical
signs including leucopenia and reduce viral shedding caused by canine
parvovirus
(types 2b and 2c), to reduce mortality and clinical signs due to
canine adenovirus
type 1 infections, to reduce clinical signs and infection or excretion
due to canine
adenovirus type 2 infections, to reduce clinical signs and infection
due to _Leptospira _
Amended pages: December 2023
AN: 02539/2021
Page 2 of 6
_canicola_ and _L. icterohaemorrhagiae_ and, to reduce pathological
signs of disease
caused by canine parainfluenza virus infections.
Onset of immunity occurs by approximately two weeks after the last
dose of the Basic
Vaccination Scheme. Onset of immunity for the canine parvovirus
component (type
2b)